Descripción de la empresa
HeartSciences Inc. operates as a medical technology firm dedicated to enhancing the clinical utility of electrocardiography through the application of artificial intelligence. The company specializes in developing AI-ECG solutions and algorithms capable of detecting impaired cardiac relaxation or cardiac dysfunction, aiming to expand the diagnostic capabilities of standard ECGs. This entity functions within the healthcare sector, specifically targeting the medical devices industry, where technological innovation is pivotal for advancing patient care and diagnostic precision. As of the latest reporting period, the company holds a market capitalization of $7.01M and reports an annual revenue of $8,669, supported by a lean workforce of 15 employees. These financial dimensions indicate that HeartSciences Inc. is a micro-cap entity with a very small revenue base relative to its market valuation, suggesting a company in an early stage of commercialization or one operating with a highly specialized, low-volume product line that relies on significant capital investment to achieve profitability.
Salud financiera
The company reported a revenue of $8,669 over the trailing twelve months, yet this nominal income is offset by a net income of $-8,485,301 and an EBITDA of $-7,768,315. The substantial disparity between the reported revenue and the negative net income reveals a cost structure where expenses far exceed sales, indicating that current operations are not self-sustaining and that the company is burning cash to fund its development efforts. Additionally, the free cash flow stands at $-4,213,324, which signifies a lack of financial flexibility to fund operations without external capital injections or debt financing. In terms of profitability metrics, the gross margin is 57.9%, suggesting that the cost of goods sold is well-controlled relative to sales; however, the operating margin is -89939.6% and the profit margin is 0.0%, highlighting severe operational inefficiencies or one-time costs that have devastated the bottom line. Regarding liquidity and leverage, the company holds $3.40M in cash against $3.87M in debt, resulting in a debt-to-equity ratio of 145.81% that characterizes a highly leveraged balance sheet rather than a conservative one. The current ratio is 1.19, indicating that the company possesses just enough current assets to cover its current liabilities, leaving little room for error regarding short-term liquidity pressures. Furthermore, the return on equity is -382.3% and the return on assets is -73.5%, metrics that reveal management is currently destroying shareholder value and failing to generate positive returns on the capital employed in the business.
Evaluación de valoración
The valuation multiples for HeartSciences Inc. reflect its status as a loss-making entity with no traditional earnings-based pricing; the P/E ratio (TTM) is N/A due to the absence of earnings, while the forward P/E is -0.78, a negative figure that implies the market is pricing in future losses or that valuation is being driven entirely by non-earnings factors. The price-to-book ratio is 2.64, indicating that the market values the company at a premium of 164% over its tangible book value, which often occurs when investors anticipate high growth potential that is not yet reflected in current assets. Alternative valuation metrics provide further insight, with a price-to-sales ratio of 808.21 and an EV/EBITDA of -0.96, suggesting that the stock is priced based on speculative future prospects rather than current operational performance or cash generation. In terms of trading range, the stock has a 52-week high of $6.47 and a 52-week low of $2.01, meaning the current price sits somewhere within this wide band, reflecting the high volatility typical of small-cap biotech and medical device firms. The beta value is 2.45, which signifies that the stock's price volatility is more than double that of the broader market, exposing investors to significant short-term price swings that are amplified by market movements.
Growth & Income
Regarding growth dynamics, the revenue growth (YoY) is N/A and the earnings growth (YoY) is N/A, reflecting the company's recent inception or the lack of sufficient historical data to calculate meaningful year-over-year expansion rates. Since the earnings are negative, it is impossible to determine if earnings are growing faster or slower than revenue; however, the absence of growth data implies the company is still in a pre-revenue or early-stage growth phase where historical comparisons are not applicable. HeartSciences Inc. does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests any available cash or raises new capital entirely into research, development, and operational scaling rather than distributing income to shareholders. Consequently, the overall growth and income profile is characterized by a complete absence of current income generation and historical growth metrics, leaving the investment thesis entirely dependent on the successful execution of the company's AI-ECG technology and its ability to transition from negative free cash flow to positive profitability in the future.